Pharmaceutical major Lupin Limited on Friday announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Nagpur Unit-1 manufacturing facility that manufactures oral solid dosage forms.
The EIR was issued after the facility was inspected in July this year.
Last week Lupin announced that it signed an agreement to acquire five legacy brands in strategic therapy areas, which include Gastroenterology, Urology and Anti-infectives from Menarini, along with the associated trademark rights. The brands include Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor).